Healthcare
Sanara MedTech Inc.(SMTI)
Live Price
Offline$22.02
+3.77% today
1Y Change
-20.85%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $180.00M
- Revenue Growth
- +19.0%
- EPS Growth
- -282.5%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sanara MedTech Inc. (SMTI) is a Healthcare stock with a market cap of $180.00M and listed on NASDAQ. The stock last traded around $22.02 and down 20.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +19.0%, EPS growth of -282.5%, a dividend yield of 0.0%. What stands out right now is revenue +19.0%, EPS -282.5%, free cash flow +953.9% with operating margin 8.9% and ROIC 16.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SMTI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+19.0% vs +7.6% peer median
Operating Margin
Below sector median
+8.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +19.0% and EPS is at -282.5%, with operating margin around 8.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +2.6% | +9.0% | +1.9% |
2026 Mar 24, 2026 | -63.6% | -9.6% | -5.0% | +10.4% |
2025 Nov 12, 2025 | +137.5% | -7.1% | -9.7% | +14.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SMTI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SMTI Max Drawdown
-54.29%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SMTI and SPY.
Company Overview
Sanara MedTech Inc.
NASDAQ Capital Market
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
- Leadership
- Seth D. Yon
- IPO Date
- Apr 7, 1994
- Employees
- 141
- Street Address
- 1200 Summit Avenue
- Mailing
- Fort Worth, TX, 76102
- Region
- Fort Worth, TX, US
- Reporting Currency
- USD
- Investor Line
- 817 529 2300
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 18.0
- Price/Sales
- 1.8
- Price/Book
- 28.7
Growth
- Revenue
- +19.0%
- EPS
- -282.5%
- Free Cash Flow
- +953.9%
Profitability
- Gross Margin
- 90.1%
- Operating Margin
- 8.9%
- Net Margin
- -36.4%
- ROE
- -178.6%
- ROIC
- 16.7%
Balance Sheet
- Debt/Equity
- 8.13
- Current Ratio
- 1.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.